WASHINGTON — Newly empowered Republican leadership in the White House and in Congress will likely bring some good news and ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Pharmaceutical manufacturing in 2024 is shaped by regulatory shifts, rising R&D expenses, and supply chain challenges, ...

In the global pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $7.5m, according to GlobalData's Deals Database.

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

The expansion was driven by lower priced items, including diabetic drugs and vitamins. “During the quarter under review, the ...

With increasing pharmaceutical production and a growing focus on patient safety, the demand for specialized and customizable ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

The government's new Rs 500 crore scheme for the medical device industry will not only boost domestic manufacturing but also ...

The mutual fund expert believes that a strategic allocation of 10-20% in the pharma and healthcare funds could benefit ...

In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.